Patent 9656098 was granted and assigned to Intraop Medical Corporation on May, 2017 by the United States Patent and Trademark Office.
The invention discloses a method of treating cancer in a patient, comprising administering to the patient a radiation sensitizer selected from nitroimidazoles in an amount effective to sensitize a patient to radiation and subjecting the patient to radiation therapy. In certain embodiments the radiation sensitizer is etanidazole or doranidazole.